Skip to main content
Enter your keywords
User account menu
Log in
Main navigation
About
History & Impact
Mission & Values
Leadership
Support SWOG
Join SWOG
Policies & Procedures
Careers
Contact Us
The SWOG Network
How We Work
Our Staff
Our Advocates
Our Partners
News & Events
News
SWOG Stories
SWOG Meetings
For Press
Clinical Trials
Biospecimen Submission
Biospecimen Access
Clinical Trials Search
Clinical Research Resources
Frequently Asked Questions
Publications
Institutions
Quality Assurance & Audits
Serious Adverse Events
Training Resources
CRA Workbench
Protocol Workbench
For Patients
Patient & Advocate Voices
Trials Open to Patients
About SWOG Cancer Trials
Joining a Trial
Section navigation
Recent Updates
1/1/2025
12/15/2024
12/1/2024
11/15/2024
11/1/2024
10/15/2024
10/1/2024
9/15/2024
9/1/2024
8/15/2024
8/1/2024
7/15/2024
All Updates
Breadcrumb
SWOG
Member Resources
Trial & Business Updates
Early Therapeutics & Rare Cancers
Priority List Early Therapeutics & Rare Cancers
CTSU/A071701
II
GENOMICALLY-GUIDED TREATMENT TRIAL IN BRAIN METASTASES
S2012
II-III
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
S1609
II
DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
CTSU/A151804
Other
ESTABLISHMENT OF A NATIONAL BIOREPOSITORY TO ADVANCE STUDIES OF IMMUNE-RELATED ADVERSE EVENTS
CTSU/EAY131
Other
Molecular Analysis for Therapy Choice (MATCH)
CTSU/NRG-GY020
III
A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
CTSU/NRG-BR004
III
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
CTSU/NRG-GY018
III
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
CTSU/A091605
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
CTSU/EA3161
II-III
A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
CTSU/NRG-HN006
II-III
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
CTSU/NRG-GY009
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
CTSU/A071401
II
Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations
CTSU/NCICOVID
Other
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
CTSU/AOST2031
AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
CTSU/AOST2032
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
CTSU/NRG-BR004
III
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer